Taro Pharma (TARO) Reports Q3 EPS of $1.37

Taro Pharma (NYSE: TARO) reported Q3 EPS of $1.37, versus $3.42 reported last year. Revenue for the quarter came in at $155.5 million, versus $220.4 million reported last year.

Net income attributable to Taro was $18.0 million compared to $139.8 million, resulting in diluted earnings per share of $0.45 compared to $3.42 for the same period last year. Excluding the impact of the aforementioned one-time tax re-measurement, net income attributable to Taro would be $54.8 million, or diluted earnings per share of $1.37.

For earnings history and earnings-related data on Taro Pharma (TARO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c